Published in J Acquir Immune Defic Syndr on August 15, 2007
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS (2008) 2.87
Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput Biol (2009) 1.78
Modeling HIV persistence, the latent reservoir, and viral blips. J Theor Biol (2009) 1.49
Can the viral reservoir of latently infected CD4(+) T cells be eradicated with antiretroviral HIV drugs? J Math Biol (2009) 1.47
Modeling the within-host dynamics of HIV infection. BMC Biol (2013) 1.29
Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips. Math Biosci (2008) 1.05
Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients. Antimicrob Agents Chemother (2014) 1.05
Incidence and correlates of HIV-1 RNA detection in the breast milk of women receiving HAART for the prevention of HIV-1 transmission. PLoS One (2012) 0.98
Transmission selects for HIV-1 strains of intermediate virulence: a modelling approach. PLoS Comput Biol (2011) 0.97
Overestimation of human immunodeficiency virus type 1 load caused by the presence of cells in plasma from plasma preparation tubes. J Clin Microbiol (2009) 0.96
A stochastic model of latently infected cell reactivation and viral blip generation in treated HIV patients. PLoS Comput Biol (2011) 0.95
HIV envelope gp120 activates LFA-1 on CD4 T-lymphocytes and increases cell susceptibility to LFA-1-targeting leukotoxin (LtxA). PLoS One (2011) 0.92
CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy. J Acquir Immune Defic Syndr (2013) 0.89
Modeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected Cells. PLoS Pathog (2015) 0.86
Short communication: HIV blips while on antiretroviral therapy can indicate consistently detectable viral levels due to assay underreporting. AIDS Res Hum Retroviruses (2013) 0.86
How effectively can HIV phylogenies be used to measure heritability? Evol Med Public Health (2013) 0.85
Targeting HIV transcription: the quest for a functional cure. Curr Top Microbiol Immunol (2015) 0.85
Contribution of follicular dendritic cells to persistent HIV viremia. J Virol (2013) 0.83
Potential influence of more-sensitive HIV-1 load detection by the new Roche Cobas AmpliPrep/Cobas TaqMan version 2.0 assay on clinical management of HIV-positive pregnant women. J Clin Microbiol (2010) 0.83
Proteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replication. Retrovirology (2013) 0.82
Analysis of multiple cell reservoirs expressing unspliced HIV-1 gag-pol mRNA in patients on antiretroviral therapy. Future Virol (2012) 0.82
The effect of opportunistic illness on HIV RNA viral load and CD4+ T cell count among HIV-positive adults taking antiretroviral therapy. J Int AIDS Soc (2013) 0.81
Transitory viremic surges in a human immunodeficiency virus-positive elite controller can shift the cellular transcriptome profile: a word of caution for microarray studies. J Virol (2008) 0.79
Therapy of HIV Infection: Current Approaches and Prospects. Acta Naturae (2017) 0.78
Frequent Episodes of Detectable Viremia in HIV Treatment-Experienced Children is Associated with a Decline in CD4+ T-cells Over Time. J AIDS Clin Res (2016) 0.77
Stochastic modelling of the eradication of the HIV-1 infection by stimulation of latently infected cells in patients under highly active anti-retroviral therapy. J Math Biol (2016) 0.76
Factors associated with HIV viral load "blips" and the relationship between self-reported adherence and efavirenz blood levels on blip occurrence: a case-control study. AIDS Res Ther (2016) 0.76
Increased inflammation in sanctuary sites may explain viral blips in HIV infection. IET Syst Biol (2016) 0.75
HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects. PLoS One (2016) 0.75
Quantitative analysis of viral persistence and transient viral load rebound from HIV clinical data. Conf Proc IEEE Eng Med Biol Soc (2011) 0.75
Virological blips and predictors of post treatment viral control after stopping ART started in Primary HIV infection. J Acquir Immune Defic Syndr (2016) 0.75
No differences in clinical outcomes with the addition of viral load testing to CD4 cell count monitoring among HIV infected participants receiving ART in rural Uganda: Long-term results from the Home Based AIDS Care Project. BMC Public Health (2016) 0.75
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 21.81
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
Decay characteristics of HIV-1-infected compartments during combination therapy. Nature (1997) 13.68
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75
Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells. Nat Immunol (2001) 9.23
New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (2003) 8.25
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med (1999) 7.07
Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol (2001) 6.78
Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory. Nat Med (2001) 5.74
Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med (1999) 5.18
Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA (1999) 4.98
Modelling viral and immune system dynamics. Nat Rev Immunol (2002) 4.98
Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med (1996) 4.72
Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet (1999) 4.36
Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA (2005) 4.24
The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med (2000) 4.08
Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA (2001) 3.73
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest (1998) 3.66
HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest (2005) 3.62
Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol (1996) 2.86
Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol (2005) 2.82
Roles of substrate availability and infection of resting and activated CD4+ T cells in transmission and acute simian immunodeficiency virus infection. Proc Natl Acad Sci U S A (2004) 2.57
The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis (1997) 2.31
Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med (1995) 2.26
Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection. J Infect Dis (2000) 2.25
Cutting edge: antigen-independent CD8 T cell proliferation. J Immunol (2001) 2.09
A cellular calculus for signal integration by T cells. Nat Immunol (2000) 2.09
Different dynamics of CD4+ and CD8+ T cell responses during and after acute lymphocytic choriomeningitis virus infection. J Immunol (2003) 2.03
Recruitment times, proliferation, and apoptosis rates during the CD8(+) T-cell response to lymphocytic choriomeningitis virus. J Virol (2001) 1.72
Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS (2002) 1.63
Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood (1995) 1.62
Estimating lymphocyte division and death rates from CFSE data. Bull Math Biol (2006) 1.53
Viral blip dynamics during highly active antiretroviral therapy. J Virol (2003) 1.51
Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus. J Infect Dis (1998) 1.47
HIV-1 infection and low steady state viral loads. Bull Math Biol (2002) 1.46
Concurrent infections and HIV pathogenesis. AIDS (2000) 1.44
Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification. AIDS (2002) 1.42
Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J Infect Dis (1996) 1.33
Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis (2000) 1.26
Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance. J Acquir Immune Defic Syndr (2001) 1.24
Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy. Math Biosci (2004) 1.14
The role of antigenic stimulation and cytotoxic T cell activity in regulating the long-term immunopathogenesis of HIV: mechanisms and clinical implications. Proc Biol Sci (2001) 1.14
Opportunistic infection as a cause of transient viremia in chronically infected HIV patients under treatment with HAART. Bull Math Biol (2005) 1.10
Antigen-driven CD4+ T cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1999) 1.08
Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons. J Infect Dis (1996) 1.03
Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure? AIDS (2002) 1.02
Models of interactions between HIV and other pathogens. J Theor Biol (1992) 0.96
Quantification of intrinsic residual viral replication in treated HIV-infected patients. Proc Natl Acad Sci U S A (2001) 0.95
Modeling the effects of vaccination on chronically infected HIV-positive patients. J Acquir Immune Defic Syndr (2002) 0.94
P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. J Antimicrob Chemother (2002) 0.93
Interferon-gamma up-regulates expression and activity of P-glycoprotein in human peripheral blood monocyte-derived macrophages. Lab Invest (1999) 0.87
Density-dependent decay in HIV-1 dynamics. J Acquir Immune Defic Syndr (2006) 0.83
Duration of an intermittent episode of viremia. Bull Math Biol (2005) 0.82
Genotypic analysis of plasma HIV-1 RNA after influenza vaccination of patients with previously undetectable viral loads. AIDS (2002) 0.82
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med (2009) 4.79
A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol (2003) 4.12
Kinetics of influenza A virus infection in humans. J Virol (2006) 3.78
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68
Acute loss of intestinal CD4+ T cells is not predictive of simian immunodeficiency virus virulence. J Immunol (2007) 3.24
Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS One (2010) 3.02
Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A (2014) 2.95
Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med (2010) 2.82
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A (2013) 2.79
Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature (2004) 2.74
Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology (2003) 2.50
Modeling sequence evolution in acute HIV-1 infection. J Theor Biol (2009) 2.32
Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A (2012) 2.27
The complexity of complexes in signal transduction. Biotechnol Bioeng (2003) 2.20
Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. J Clin Invest (2012) 2.05
Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr (2004) 2.05
Different dynamics of CD4+ and CD8+ T cell responses during and after acute lymphocytic choriomeningitis virus infection. J Immunol (2003) 2.03
Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection. J Virol (2010) 2.02
Kinetics of hepatitis C virus reinfection after liver transplantation. Liver Transpl (2006) 2.01
Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology (2007) 2.00
CD8+ lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells. PLoS Pathog (2010) 1.99
Determining the relative efficacy of highly active antiretroviral therapy. J Infect Dis (2003) 1.90
Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy. J Theor Biol (2007) 1.89
Designing a genome-based HIV incidence assay with high sensitivity and specificity. AIDS (2011) 1.88
Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology (2011) 1.87
Turnover rates of B cells, T cells, and NK cells in simian immunodeficiency virus-infected and uninfected rhesus macaques. J Immunol (2003) 1.87
In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: why are CD4+ but not CD8+ T cells depleted? Proc Natl Acad Sci U S A (2002) 1.82
Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus. J Virol (2010) 1.80
Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput Biol (2009) 1.78
Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infection. J Virol (2004) 1.77
Simulation and prediction of the adaptive immune response to influenza A virus infection. J Virol (2009) 1.76
Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol (2007) 1.74
ON IDENTIFIABILITY OF NONLINEAR ODE MODELS AND APPLICATIONS IN VIRAL DYNAMICS. SIAM Rev Soc Ind Appl Math (2011) 1.69
Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology (2006) 1.69
Polyspecificity of T cell and B cell receptor recognition. Semin Immunol (2007) 1.68
Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut (2013) 1.63
Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog (2012) 1.61
Impact of thymectomy on the peripheral T cell pool in rhesus macaques before and after infection with simian immunodeficiency virus. Eur J Immunol (2005) 1.60
Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection. J Virol (2011) 1.57
Parameter identifiability and estimation of HIV/AIDS dynamic models. Bull Math Biol (2008) 1.56
Drug resistance and influenza pandemics. Lancet (2002) 1.55
Estimating lymphocyte division and death rates from CFSE data. Bull Math Biol (2006) 1.53
Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance. J Acquir Immune Defic Syndr (2005) 1.52
Short-lived infected cells support virus replication in sooty mangabeys naturally infected with simian immunodeficiency virus: implications for AIDS pathogenesis. J Virol (2008) 1.51
Viral blip dynamics during highly active antiretroviral therapy. J Virol (2003) 1.51
Modeling amantadine treatment of influenza A virus in vitro. J Theor Biol (2008) 1.51
Modeling HIV persistence, the latent reservoir, and viral blips. J Theor Biol (2009) 1.49
Simian immunodeficiency virus SIVagm dynamics in African green monkeys. J Virol (2008) 1.49
Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques. Proc Natl Acad Sci U S A (2007) 1.48
Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. Gastroenterology (2005) 1.47
HIV-1 infection and low steady state viral loads. Bull Math Biol (2002) 1.46
Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis (2002) 1.45
Estimating time since infection in early homogeneous HIV-1 samples using a poisson model. BMC Bioinformatics (2010) 1.45
Agent-based modeling of host-pathogen systems: The successes and challenges. Inf Sci (Ny) (2009) 1.43
Multiplicity of human immunodeficiency virus infections in lymphoid tissue. J Virol (2004) 1.43
Complete genetic linkage can subvert natural selection. Proc Natl Acad Sci U S A (2007) 1.42
Mathematical analysis of delay differential equation models of HIV-1 infection. Math Biosci (2002) 1.41
Modeling and estimation of replication fitness of human immunodeficiency virus type 1 in vitro experiments by using a growth competition assay. J Virol (2006) 1.41
Dynamic correlation between intrahost HIV-1 quasispecies evolution and disease progression. PLoS Comput Biol (2008) 1.39
Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay. J Theor Biol (2004) 1.39
HIV dynamics with multiple infections of target cells. Proc Natl Acad Sci U S A (2005) 1.36
Acute hepatitis A virus infection is associated with a limited type I interferon response and persistence of intrahepatic viral RNA. Proc Natl Acad Sci U S A (2011) 1.36
Quantifying T lymphocyte turnover. J Theor Biol (2013) 1.35
Viral and latent reservoir persistence in HIV-1-infected patients on therapy. PLoS Comput Biol (2006) 1.35
Naïve and memory cell turnover as drivers of CCR5-to-CXCR4 tropism switch in human immunodeficiency virus type 1: implications for therapy. J Virol (2006) 1.31
Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog (2012) 1.30
Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. AIDS (2003) 1.30
Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy. J Hepatol (2002) 1.30
Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection. J Virol (2011) 1.28
Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. PLoS Pathog (2012) 1.28
Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. J Infect Dis (2003) 1.27
Modeling within-host dynamics of influenza virus infection including immune responses. PLoS Comput Biol (2012) 1.26
Characterizing T cell movement within lymph nodes in the absence of antigen. J Immunol (2007) 1.24
Estimates of intracellular delay and average drug efficacy from viral load data of HIV-infected individuals under antiretroviral therapy. Antivir Ther (2004) 1.23
Influence of peak viral load on the extent of CD4+ T-cell depletion in simian HIV infection. J Acquir Immune Defic Syndr (2006) 1.23
Modeling subgenomic hepatitis C virus RNA kinetics during treatment with alpha interferon. J Virol (2009) 1.23
Use of laser capture microdissection to map hepatitis C virus-positive hepatocytes in human liver. Gastroenterology (2013) 1.23
Determining thymic output quantitatively: using models to interpret experimental T-cell receptor excision circle (TREC) data. Immunol Rev (2007) 1.23
Modeling HCV kinetics under therapy using PK and PD information. Expert Opin Drug Metab Toxicol (2009) 1.22
Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J Antimicrob Chemother (2008) 1.21
Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells. J Virol (2006) 1.21
How antigen quantity and quality determine T-cell decisions in lymphoid tissue. Mol Cell Biol (2008) 1.20
Dynamics of hepatitis B virus infection. Microbes Infect (2002) 1.20
A stochastic model of cytotoxic T cell responses. J Theor Biol (2004) 1.20
The role of cells refractory to productive infection in acute hepatitis B viral dynamics. Proc Natl Acad Sci U S A (2007) 1.19
Influenza A virus infection kinetics: quantitative data and models. Wiley Interdiscip Rev Syst Biol Med (2010) 1.18
Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b. Semin Liver Dis (2003) 1.18
Evolution of hepatitis C viral quasispecies after liver transplantation. Gastroenterology (2002) 1.18
Modeling and estimation of kinetic parameters and replicative fitness of HIV-1 from flow-cytometry-based growth competition experiments. Bull Math Biol (2008) 1.17
Kinetics of coinfection with influenza A virus and Streptococcus pneumoniae. PLoS Pathog (2013) 1.16
Stochastic theory of early viral infection: continuous versus burst production of virions. PLoS Comput Biol (2011) 1.15
Current estimates for HIV-1 production imply rapid viral clearance in lymphoid tissues. PLoS Comput Biol (2010) 1.15
Dynamics of T- and B-lymphocyte turnover in a natural host of simian immunodeficiency virus. J Virol (2007) 1.15
Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy. Math Biosci (2004) 1.14
Viral dynamics during primary simian immunodeficiency virus infection: effect of time-dependent virus infectivity. J Virol (2010) 1.14